M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project PharmaTimesPartnership grants Lilly global rights to Alzstatin ACD680NeuroscienceRead full story pharminent June 9, 2026 (Last updated: June 9, 2026) PharmaTimes Partnership grants Lilly global rights to Alzstatin ACD680 Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data Related Stories M&A / Deals GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year pharminent June 9, 2026 M&A / Deals J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B pharminent June 8, 2026 M&A / Deals Incyte gobbles up Star’s Vega haematology unit in $2bn deal pharminent June 8, 2026
